

New methods: miniorgans

C. Rovida

CAAT-Europe, University of Konstanz

16 maggio 2018

Parma Summer School 2018

Emerging Risks for Food Safety and Public Perception


1981



2010



Universität
Konstanz



JOHNS HOPKINS
BLOOMBERG SCHOOL
of PUBLIC HEALTH



www.ecopa.eu

2012




**Stakeholder
Platform**



**Transatlantic
Hub**




**CAAT EU Policy
Program**





www.team-mastery.eu



urope





Regulation EC 1107/2009 on Plant Protection Products

Regulation EC 1223/2009 on cosmetics Products



Regulation EC 528/2012 on Biocidal Products



Toxicology: traditional in vivo approach

- Skin/Eye irritation
- Skin sensitisation
- Acute toxicity
- Repeated Dose Toxicity
- Reproductive Toxicity
- Genotoxicity
- Carcinogenicity



We are not 70kg rats !!!

Age 0 -100 years

Mostly 3 months,
max 2 years

Different ethnics,
both gender

2-200 kg

20-500 g

Mostly twins,
one gender

Diverse food,
environment



Standardized
chow and cage

Disease history,
Comorbidities,
Multiple treatments

Healthy,
Artificial diseases,
Mono-treatments


RELIABILITY OF ANIMAL TESTS

GLP, standardized protocols, some validated, high doses, substance effects in healthy animals:

- **Cancer bioassay: 57% (repeat or mouse vs. rat)**
- **Reproductive Tox: 60% between species**
- **Uterotrophic assay: 26% contradictory**
- **Skin sensitization: 77% guinea pig vs. mouse**
- **Severs eye irritation: 70% reproducible**
- **Acute fish tox: up to 6 log orders different**
- **Chronic tox: no correlation between mouse and rats or genders**




How can we do quantitative risk assessment, if already oral bioavailability differs dramatically?




Grass GM and Sinko PJ. *Adv Drug Delivery Rev* 2002, 43:433-451

Report del National Research Council of the National Academies Published on 2007




(Google: "Toxicity Testing in the 21st Century")

A New Paradigm: Activation of Toxicity Pathways



(Courtesy of Mel Andersen)

ADVERSE OUTCOME PATHWAY




IATA

Decision Context

Exposure


ADME





Endpoint of concern

Regulatory question


Guidance Document for the Use of Adverse Outcome Pathways in Developing Integrated Approaches to Testing and Assessment (IATA)



Series on Testing and Assessment
No. 260



Effectopedia is a collaborative research platform, facilitating knowledge exchange between **experimental biologists, modelers and chemical risk assessment communities.**



An initial set of **training material** and videos are available on Effectopedia training website <http://training.effectopedia.org/>

From the website you can **learn how to:**

- Create the visual diagram of an AOP
- Build Key Event and Key Event Relationship following the OECD Users' Handbook for AOP development.
- Save an AOP as a local file or publish it on the centralised Effectopedia database
- Build simple quantitative models using experimental data
- Design and implement interactive executable models using R or Matlab

Effectopedia is a free open source software distributed under GNU General Public License v3.0. The most recent version is available for download from:

Effectopedia website
<http://effectopedia.org>

The source code is available on SourceForge :
<https://sourceforge.net/projects/effectopedia/>

Effectopedia is developed by:



with the financial support of



European Commission

 **Effectopedia**
The Online Encyclopedia of Adverse Outcome Pathways

 OECD
Jan, 2017

AOP wiki – search for «cancer»

AOPWiki
AOPs
Key Events
KE Relationships
Stressors
sign in sign up

AOP Title Search

Id	Title ▲
139	Alkylation of C
220	Chronic Cyp2 Liver Cancer
199	ER mediated l
200	Estrogen rece breast cancer
37	PPARalpha-d

Network View ?

Legend:

- MIE: Blue square (MIE:1)
- KE: Green circle (KE:2)
- AO: Yellow square (AO:3)
- Other AOP including this KE: Grey triangle (57)
- Indirect relationship: Dotted line with arrowhead
- Direct relationship: Solid line with arrowhead
- *Width of line reflects strength of evidence for relationship

AOP Fulltext Search


Id	Title ▲	Mol	Description	Status	Project	OECD Project
200	Estrogen receptor activation leading to breast cancer	Molly M Morgan	Under development: Not open for comment. Do not cite	Under Development		

Help
About
FAQ
Metrics

© 2012, Johns Hopkins University and the University of Konstanz. All Rights Reserved.


Type of Cells for Toxicity studies

- **Cell Lines**
 - Origine tumorale
- **Primary cells**
 - Biopsy
 - Volunteers (plasma, urine, etc.)
- **Stem Cells**
 - Adult Stem Cells
 - Embryo stem cells
 - Cord Blood Stem Cells
 - Embryos (animal origin)



Traditional culture: pan-fried eggs “sunny side up”

Cell density ca. 0.1% of tissue,
Dilution of all secreted factors






- Ca. 25% of cell lines misidentified
- 15-25% mycoplasma infected
- Genetic instability
- Culture artifacts

No flow

No steady ingredients,

Cell to cell contact about 2%,
49% plastic, 49% medium






validation
 performance predictive
 confidence
in vivo relevance

Application of the adverse outcome pathway concept

- **Human-induced pluripotent stem cell technology**
- **Human organ-on-a chip**
- **Ex-vivo biopsy or post-mortem human tissue**
- **Bio-banks and advanced mathematical modelling**
- **Advanced clinical studies**

Induced pluripotent stem cells (iPSC)



iPSC Availability

Human Pluripotent Stem Cell Registry

 Search cell lines

Examples: BCRTI001-A, Trisomy 13, Spain

 Register cell line

 Register project

Last validated lines

[WTSII717-B](#) [WTSII638-B](#) [WTSII699-B](#) [WTSII659-B](#) [WTSII657-B](#) [WTSII687-B](#) [WTSII693-B](#)

What is hPSCreg?

hPSCreg offers the research community, legislators, regulators and the general public at large an in-depth overview on the current status of human pluripotent stem cell (hPSC) research.

[newsletter subscription](#)

 Follow @hpscereg


News

 Current status: 738 hESC lines and 1595 iPSC lines

 Current status: 737 hESC lines and 1756 iPSC lines

 New: Provide public comments or feedback for cell lines

EU / World



Limitations and Challenges

2D *in vitro*

Lack organ function, structure and complexity

Cancer or immortalized cells

3D *in vitro*

Lower reproducibility

Endpoints generally need optimization from 2D

Challenge to study on a single cell level

Limited perfusion

Organ-on-chip

Costly and complex

Low availability

Demands engineering skills

Not suitable for high-throughput screening

Organ specific biomarkers

“All models are wrong, but some are useful”

George EP Box (2005): Statistics for Experimenters (2nd ed.) p 440

Your scientific question should determine which model to use

Why 3D cell cultures?



Alépée et al., ALTEX
2014, 31, 441-477.

t4 Workshop Report*


State-of-the-Art of 3D Cultures (Organs-on-a-Chip) in Safety Testing and Pathophysiology

Natalie Alépée¹, Anthony Bahinski², Mardas Daneshian³, Bart De Wever⁴, Ellen Fritsche⁵, Alan Goldberg⁶, Jan Hansmann⁷, Thomas Hartung^{3,6}, John Haycock⁸, Helena T. Hogberg⁶, Lisa Hoelting⁹, Jens M. Kelm¹⁰, Suzanne Kadereit⁹, Emily McVey¹¹, Robert Landsiedel¹², Marcel Leist^{3,9}, Marc Lübberstedt¹³, Fozia Noor¹⁴, Christian Pellevoisin¹, Dirk Petersohn¹⁵, Uwe Pfannenbecker¹⁶, Kerstin Reisinger¹⁵, Tzutzuy Ramirez¹², Barbara Rothen-Rutishauser¹⁷, Monika Schäfer-Korting¹⁸, Katrin Zeilinger¹³ and Marie-Gabriele Zurich^{19,20}

- Increased cell survival
- Increased differentiation
- Increased cell – cell interaction
- Reproducing better the complexity of the organ
- Endpoints need optimization
- More complex – lower reproducibility



Increasing complexity



- *Ease of Use: Throughput*
- *Reproducibility*
- *Genetic Manipulation*

- *Physiological Relevance*
- *Interplay of Different Cell Types*
- *Longterm Drug Exposure*

Specific, established Mechanism can be assessed

Holistic Models for MoA Analysis & Hypothesis Generation

Funk & Roth. Arch Toxicol. 2017

ORGANOTYPIC CULTURES

Goal is to replicate human ORGAN-LEVEL functions *in vitro*,

- Composed of 2 or more tissues that exhibit unique functions when they are interfaced
- Perfused by blood flowing through endothelium-lined vessels
- Controlled by chemical and molecular factors produced by constituent cells or delivered through the vasculature
- Regulated by mechanical forces (e.g., due to motion, breathing, peristalsis) and blood flow
- Structured to secrete or transport factors in specific directions
- Infiltrated with immune cells during inflammatory responses
- Physiologically coupled to other organs via factors transmitted in blood flowing through linking vessels

Courtesy of Wyss Institute

R O U T E S O F E X P O S U R E





Skin

Intestine

Lung




L O C A L E X P O S U R E




S Y S T E M I C E X P O S U R E




Full PBPK Model with Time-Dependent Volume



V PROMPT

VANDERBILT-PITTSBURGH RESOURCE FOR ORGANOTYPIC
MODELS FOR PREDICTIVE TOXICOLOGY






BIODESIGN PRINCIPLES:

- Tissue-Tissue Interface
- Dynamic Flow
- Cyclic Breathing Movements

Peristaltic Human Gut-on-a-Chip


(Kim et al., *Lab on a Chip* 2012 & *Integrative Biology* 2013)

Human Intestine





PNAS, 2007, 104:10295


Microfluidic Platform



Human Gut Epithelium (Caco-2 cell monolayer in Microfluidic)



24 hr after seeding






+ Peristaltic-like motions

Gut Chip

Bioprinter

- Living cells + Hydrogel
- Matrix for the scaffolds
- Multilayers





Early Alternatives

Today

Future

Cell Culture
(one cell type, few parameters)

Organo-typic Cell Culture
(Coculture, Organ function, often Perfusion)

Human-on-chip
(Multi-Organ Models With Microfluidics)

Cell Culture + Omics or Image Analysis (high-content)

Toxicity Mechanisms
("Adverse Outcome Pathways", "Human Toxome")

Automated Cell Culture (high-throughput Screening)

Structure / Activity-Relationships
(Correlations)

Integrated Test Strategies
(combined tests)

Systems Toxicology
("Virtual Patient")

Modeling
(Receptor binding, Virtual Organs, Kinetics)

In case you want to know more


- www.altex.ch
- <http://altweb.jhsph.edu>
- <http://academy.altertox.be/>
- www.estiv.org



15–18 October 2018
in Berlin, Germany.


20th

International congress
on In Vitro Toxicology



**Heavier-than-air flying
machines are impossible
(1895)**

**No balloon and no
aeroplane will ever be
practically successful
(1902)**



**William Thomson, known as Lord Kelvin (1824-1907),
President of the Royal Society and inventor of the absolute temperature scale**

Thank you for the attention!!!

